Systematic evaluation and meta-analysis of acipimos co-administrated with statin in hyperlipemia treatment
QIU Meng
YAN Ying-ying
LIU Fang
ZHU Yun
Abstract：Objective To evaluate the efficacy and safety of acipimos co-administrated with statin in hyperlipemia treatment by systematically evaluated and meta-analyze published studies of randomized controlled trials and quasi-randomized control trials.Methods Databases including PubMed, EMbase, Cochrane Central Register of Controlled Trials, CNKI, WanFang, VIP Database and Clinical Trials were searched electrically to collect literatures published from database foundation to Feb 2015. The relevant periodicals and references of the included studies were manually retrieved. Two reviewers independently screened and determined the eligibility of study, extracted data and assessed the quality of each included study. The meta-analysis was conducted using RevMan 5.1 software.Results A total of 19 studies involving 1895 patients were included. The results of meta-analysis showed that, compared with statin monotherapy, acipimos co-administrated with statin was associated with a statistically significant in Total cholesterol lipoprotein (SMD=-0.57, 95%CI: -0.98~-0.17,P<0.00001), low-density lipoprotein cholesterol (SMD=-1.33,95%CI: -2.01~-0.65,P<0.00001), triglyceride (SMD=-1.74, 95%CI: -2.31~-1.16,P<0.00001), and high-density lipoprotein cholesterol (SMD=1.74, 95%CI: 1.14~2.34,P<0.00001). Adverse reactions were higher when using acipimos co-administrated with statin than using statin monotherapy (OR=1.55, 95%CI: 1.09~2.21,P=0.002).Conclusion Acipimos combined with statin has better effects in reducing the lipid level compared with statin monotherapy, with higher adverse reactions rate.
Keywords：AcipimosStatinHyperlipemiaMeta-analysis
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 6-9,18 )